The Market and Potential for CRISPR/Cas9 Gene Editing

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,995	101 Pages	Kalorama Information	February, 2018	KLI15596715

Best Price Guarantee
Price	from $3,995
Length	101 Pages
Publisher	Kalorama Information
Published Date	February, 2018
SKU	KLI15596715

The Market and Potential for CRISPR/Cas9 Gene Editing

This report consolidates the information and trends and provides reliable market estimates for CRISPR technology to 2023. As part of the report's coverage, it provides the following:

Market Size and Forecast for CRISPR/Cas9 Gene Editing, 2017-2023
The Market for CRISPR/Cas9 by Region (N. Amer. EU, ROW), 2017-2023 Analysis of Growth Trend by Region
Market by Application (Cancer Research, Non-Cancer Disease Research, Cancer Diagnostics, Infection Diagnostics, Plant, Food, Biofuel, Drug Discovery, Drug Development, Other)
Growth Trend, U.S.
Growth Trend, Outside U.S.
Market by End User (Hospitals, University, Medical Research Institute, Government), 2017
Market by End User (Hospitals, University, Medical Research Institute, Government), 2023
Recent Technology and Market Developments and Medical Studies
Partnerships Involving CRISPR Gene Editing

Companies in the Market and Partnerships in Gene Editing

In 2018, more than 30 players participate in this market, from large multinational corporations to small, niche life sciences companies. Key players include Agilent, MilliporeSigma, GE Healthcare Dharmcon, GeneScript, Horizon Discovery Group, OriGene, ThermoFisher Scientific, Transposagen, and ToolGen. These companies develop and commercialize various products and services for each of the major gene editing technologies.

The nature of CRISPR’s complex technology requires partnerships between the developers of the technology and the healthcare concerns with distribution strength and a broader product base. These developments are outlined in the report.

Recent Lawsuit and Industry Risk Analysis

Currently, one of the more significant factors in commercializing CRISPR-Cas9 as a viable therapeutic tool is the current legal battles surrounding the technology. The issue started when both the University of California, Berkeley (UCB) and the Broad Institute of MIT (the Broad) both filed patents related to this technology. While there's been some resolution, the report provides an analysis of developments.

Executive Summary
- Overview
  - gRNA
  - Enzyme
    - Table PubMed References for "CRISPR" 2011-est. 2018
- NIH Grants for CRISPR Projects
  - Table Grants for CRISPR-based Projects, NIH
  - CRISPR/Cas9 NIH Projects by End User
    - Table NIH Project Grant Recipients by type
- Industry Risk Analysis - Patent Landscape
  - Impact of the Initial Ruling
  - How Things Stand Now in the US
  - How Things Stand in Europe
  - Conclusions
- Other Recent CRISPR/Cas9 Developments
- The Market for CRISPR Equipment and Supplies
  - Table Market for CRISPR Technologies, 2017-2023
  - Market by Geography
    - Table CRISPR Gene Editing Market, 2017-2023
- Trends in Gene Editing
  - Table Significant Trends in the Market for Gene Editing Technologies, 2016
- Significant Partnerships in Gene Editing
  - Table Selected Gene Editing Partnerships
CRISPR Products and Trends
- Overview
  - Advantages and Disadvantages of CRISPR
    - Table Advantages and Limitations of CRISPR-Cas9 Technology in Gene Editing, 2016
- Recent Applications and Developments
  - Malaria Control
  - Gene-Edited Sheep for Regenerative Medicine
  - Improved Vaccine Creation
  - Obesity Control
  - Epstein-Barr Virus
  - Protein Coding
  - Improving Chinese Herbs
  - Identifying Drug Resistance Mutations
  - Immune Therapies for Cancer
  - Enabling Bacterial Cell Factories
  - Muscular Dystrophy
  - ""Piggy Bac" Process for Stem Cells
  - Clarity on Salmonella Ser. Kentucky
  - Better Human Disease Models
  - Editing of Bread Wheat
  - Cancer Cell Phagocytosis
  - Refining Gene Editing
- Companies in CRISPR Gene Editing
  - Table Products on the Market
- Commercial Applications of Gene Editing Technologies
- Using CRISPR for Diagnostics
- Using CRISPR for Human Therapeutics
  - Table Gene Editing-Based Therapies
  - Selected CRISPR-Cas9 Gene Editing Products
    - Table Commercial Gene Editing Products on the Market
- CRISPR Companies
  - Agilent
  - Allele Biotechnology
  - Applied Biological Materials
  - Dharmacon
  - DNA 2.0
  - GeneCopoeia
  - GenScript
  - Horizon Discovery Group, Plc
  - Integrated DNA Technologies
  - MilliporeSigma
  - OriGene
  - PNA Bio
  - Santa Cruz Biotechnology
  - System BioSciences
  - Takara Bio (Clontech)
  - ThermoFisher Scientific
  - ToolGen
  - TriLink Biotechnology
    - Table Significant Trends in the Market for Gene Editing Technologies, 2018
Gene Editing Market Analysis
- Market Analysis Commentary
- The Market for CRISPR Equipment and Supplies
  - Table Market for CRISPR Technologies, 2017-2023
  - Market by Geography
    - Table CRISPR Gene Editing Market (N. Amer. EU, ROW), 2017-2023
- Growth Trend
  - Table Growth Trend in the CRISPR Market, 2017-2022
  - Growth Trend in North America and Europe
    - Table Growth Trend in North America and Europe
  - Growth Trend in the Rest of the World
    - Table Growth Trend in the Rest of the World
- Market by Application
  - Table Market by Application (Cancer Research, Non-Cancer Disease Research, Cancer Diagnostics, Infection Diagnostics, Plant, Food, Biofuel, Drug Discovery, Drug Development, Other)
- Market by End User
  - Table Market by End User (Hospitals, University, Medical Research Institute, Government), 2017
  - Table Market by End User (Hospitals, University, Medical Research Institute, Government), 2023
Gene Editing Partnerships
- Caribou Biosciences, Inc.
- Sangamo Biosciences
  - Shire International
  - Pfizer Inc.
  - Bioverativ Inc.
- CRISPR Therapeutics
  - Bayer
  - Vertex Pharmaceuticals
  - MaSTherCell
  - Neon Therapeutics
  - Massachusetts General Hospital Cancer Center
  - CureVac AG
- Editas Medicine
  - Allergan plc
  - Adverum
  - Juno Therapeutics
- Intellia Therapeutics
  - Regeneron Pharmaceuticals
  - Novartis
- Precision Biosciences
- BlueBird Biotechnologies
- Christiana Care's Gene Editing Institute
  - The Wistar Institute
  - NovellusDx
  - Analytical Biological Services
- Casebia Therapeutics
  - CRISPR Therapeutics and MaxCyte
  - Seattle Children's Research
  - CRISPR Therapeutics and CureVac AG
- Synthego
  - Thermo Fisher Scientific
- Sarepta Therapeutics
- Homology Medicines
- GenScript
- Cellectis, Inc.
  - Pfizer
  - Servier
- Merck
- Twist Bioscience, Desktop Genetics
- AstraZeneca
  - The Wellcome Trust Sanger Institute
  - The Innovative Genomics Initiative
  - Thermo Fisher Scientific
  - Broad Institute / Whitehead Institute
    - Table Selected Gene Editing Partnerships
- Increasing Investments and Funding in Gene Editing Area to Augment Market Revenues
  - Exonics Therapeutics
  - Synthego
  - Homology Medicines
  - Editas Medicine
  - Intellia Therapeutics
  - CRISPR Therapeutics
  - Poseida Therapeutics
  - Recombinetics
    - Table Selected Gene Editing Investments